This database contains 43 studies, archived under the term: "disease progression"
Click here to filter this large number of results.
Treatment of sleep apnoea syndrome decreases cognitive decline in patients with Alzheimer’s disease
Troussière, Anne-Cécile,
Monaca Charley, Christelle,
Salleron, Julia,
Richard, Florence,
Delbeuck, Xavier,
Derambure, Philippe,
Pasquier, Florence,
Bombois, Stéphanie
Background: It is essential to detect and then treat factors that aggravate Alzheimer’s disease (AD). Here, we sought to determine whether or not continuous positive airway pressure (CPAP) therapy for sleep apnoea syndrome (SAS) slows the rate of cognitive decline in mild-to-moderate AD patients.; Methods: Between January 2003 and June 2011, we included consecutive, mild-to-moderate […]
Angiotensin-converting enzyme inhibitors and Alzheimer’s disease progression in older adults: results from the Réseau sur la Maladie d’Alzheimer Français cohort
Soto, Maria E.,
Abellan van Kan, Gabor,
Nourhashemi, Fati,
Gillette-Guyonnet, Sophie,
Cesari, Matteo,
Cantet, Christelle,
Rolland, Yves,
Vellas, Bruno
Objectives: To assess whether angiotensin-converting enzyme inhibitor (ACE-I) treatment is associated with less cognitive decline in older adults with Alzheimer’s disease (AD) than in those using other hypertensive or no drugs.; Design: Four-year prospective multicenter cohort study with a biannual assessment.; Setting: Memory clinics from 16 university hospitals in France.; Participants: Community-dwelling older adults with […]
Platelet decline as a predictor of brain injury in HIV infection
Ragin, Ann B.,
D’Souza, Gypsyamber,
Reynolds, Sandra,
Miller, Eric,
Sacktor, Ned,
Selnes, Ola A.,
Martin, Eileen,
Visscher, Barbara R.,
Becker, James T.
An association between platelet decline and increased risk of progression to dementia has been observed in an advanced HIV infection cohort study. This investigation evaluated the prognostic significance of platelet decline for dementia, for psychomotor slowing, and for brain injury, as quantified in vivo, in a much larger population of HIV+ men. Platelet counts and […]
Impact of molecular imaging on the diagnostic process in a memory clinic
Ossenkoppele, Rik,
Prins, Niels D.,
Pijnenburg, Yolande A.L.,
Lemstra, Afina W.,
van der Flier, Wiesje M.,
Adriaanse, Sofie F.,
Windhorst, Albert D.,
Handels, Ron L.H.,
Wolfs, Claire A.G.,
Aalten, Pauline,
Verhey, Frans R.J.,
Verbeek, Marcel M.,
van Buchem, Mark A.,
Hoekstra, Otto S.,
Lammertsma, Adriaan A.,
Scheltens, Philip,
van Berckel, Bart N.M.
Background: [(11)C]Pittsburgh compound B ([(11)C]PIB) and [(18)F]-2-fluoro-2-deoxy-D-glucose ([(18)F]FDG) PET measure fibrillar amyloid-β load and glucose metabolism, respectively. We evaluated the impact of these tracers on the diagnostic process in a memory clinic population.; Methods: One hundred fifty-four patients underwent paired dynamic [(11)C]PIB and static [(18)F]FDG PET scans shortly after completing a standard dementia screening. Two-year […]
Slowing progression of early stages of AD with alternative therapies: a feasibility study
This pilot study identified the feasibility and efficacy of the effect of combining healing touch (HT) and body talk cortices (BTC) on the progression of Alzheimer’s disease (AD). Both HT and BTC elicit the relaxation response and support cognitive function from two different perspectives. A two-group, repeated measures design was used. Subjects (n = 22), 65 or […]
What effect does a structured home-based exercise programme have on people with Huntington’s disease? A randomized, controlled pilot study
Khalil, H.,
Quinn, L.,
van Deursen, R.,
Dawes, H.,
Playle, R.,
Rosser, A.,
Busse, M.
Objective: The aim of this study was to explore feasibility, safety and outcome of an exercise intervention in people with Huntington’s disease.; Design: A randomized controlled pilot trial.; Setting: A home-based exercise programme.; Subjects: A total of 25 subjects with early to mid-stage Huntington’s disease.; Intervention: Subjects were randomly allocated to either an exercise intervention […]
Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study
Ikeda, Manabu,
Mori, Etsuro,
Kosaka, Kenji,
Iseki, Eizo,
Hashimoto, Mamoru,
Matsukawa, Noriyuki,
Matsuo, Kazutaka,
Nakagawa, Masaki
Background/aims: To investigate the safety and efficacy of long-term administration (52 weeks) of donepezil in patients with dementia with Lewy bodies (DLB).; Methods: This was a 52-week, multicenter, open-label extension study. Up to 8 weeks after the completion of the preceding randomized, placebo-controlled trial (RCT), patients started treatment with 3 mg of donepezil daily for […]